Polycomb Repressive Complex 2 promotes atherosclerotic plaque vulnerability
Divyesh Joshi, Raja Chakraborty, Tejas Bhogale, Jessica Furtado, Hanqiang Deng, James G. Traylor, Anthony Wayne Orr, Kathleen A. Martin, Martin Alexander Schwartz
This study identifies PRC2 as a driver of atherosclerosis by suppressing Klf2/4, and shows that inhibiting PRC2 with tazemetostat reduces plaque progression and improves stability.
bioRxiv · Dec 2, 2024 · PreprintCell Biology